Clinical trials: Diabetic Retinal Disease
Type 1 Diabetes, Neuropathy
Corneal Confocal Microscopy to Detect Diabetic Neuropathy in Children
The overall aim of this study is to confirm the utility of corneal confocal microscopy (CCM) as a new technique to rapidly and non-invasively assess diabetic neuropathy (DN) in children.
- Conditions
- Type 1 Diabetes, Neuropathy, Retinopathy
- Trial name
- CCM (NCT02321904)
- Testing
- Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing
- Where
- Canada
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Proliferative Diabetic Retinopathy
25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR.
- Trial name
- RaTAPDR (NCT02328118)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- China
- Volunteers
- 120 people
- Sponsor
- JUNYAN ZHANG
Diabetic Retinopathy
Prevention of Onset and Transition to an Advanced Form of Diabetic Retinopathy in Children
The primary goal of the project is to create a normative database from data collected from a healthy pediatric population. A secondary aim is to compare normative data with data from pediatric patients with pre-existing type 1…
- Trial name
- NCT05615740
- Testing
- Optical coherence tomography (OCTA)
- Where
- Czechia
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- University Hospital Ostrava
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema
Ultra-wide field fluorescein angiography can detect the response of anti VGEF therapy such as Avastin on retinal ischemia in the setting of diabetic macular edema.
- Conditions
- Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT02096874
- Testing
- Bevacizumab
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- King Khaled Eye Specialist Hospital
Type-2 Diabetes, Diabetic Retinopathy
Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)
To characterise phenotypes of Non Proliferative Diabetic Retinopathy (NPDR) progression using multimodal testing/imaging procedures.
- Trial name
- NCT01440660
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Proliferative Diabetic Retinopathy
Bevacizumab and Long Acting Gas in Diabetic Vitrectomy
Persistent or recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy complications is a common occurrence with an incidence of 12% to 63%.
- Trial name
- NCT00656435
- Testing
- Bevacizumab
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- National Taiwan University Hospital
Neovascular Age-related Macular Edema, Diabetic Macular Edema
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of…
- Conditions
- Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05222633
- Testing
- Ranibizumab, Aflibercept, Conbercept
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wenbin Wei
Diabetic Retinopathy
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various…
- Trial name
- NCT00542178
- Testing
- Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment
- Where
- 7 sites in United States, Canada
- Volunteers
- 3,472 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Retinal Disease
Evaluation and Treatment of Patients With Retinal Disease
This study offers evaluation and treatment for patients with certain diseases of the retina (the layer of light-sensitive tissue that lines the inside of the eyeball).
- Trial name
- NCT00005784
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation
VISUPRIME® Eye Drops
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
- Conditions
- Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT05677685
- Testing
- VISUPRIME
- Where
- 6 sites in Italy
- Volunteers
- 78 people
- Sponsor
- VISUfarma SpA
Diabetic Retinopathy
Automated Screening of Diabetic Retinopathy Using a Smartphone-based Camera
The prevalence of diabetic retinopathy (DR) in the UK is on the rise. Within 20 years of diabetes diagnosis, nearly all people with type 1 and almost two thirds of people with type 2 diabetes (60%) have some degree of DR.
- Trial name
- NCT04732208
- Testing
- Colour fundus photography
- Where
- United Kingdom
- Volunteers
- 410 people
- Sponsor
- Tameside General Hospital
Diabetic Retinopathy
The Diabetic Retinopathy Screening, Prevention and Control Program
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness.
- Trial name
- NCT04240652
- Where
- 2 sites in China
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Retinopathy Visually Threatening
Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy
Subject/Participant Groups: Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment Control Group: Subjects do not undergo ILM peeling during…
- Trial name
- NCT04380064
- Testing
- ILM Peeling, No ILM Peeling
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- Rush Eye Associates
Diabetic Retinopathy
Screening for Diabetic RETINopathy Using a Non-mydriatic Retinograph Funduscope in Occupational MEDicine
Diabetic retinopathy is a complication of diabetes that can affect vision. Early detection and appropriate management can help prevent or delay vision loss.
- Trial name
- RETINOMED (NCT07828821)
- Testing
- Non-mydriatic retinography, Self-administered questionnaire
- Where
- France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Clermont-Ferrand
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- ReFineDR (NCT04477707)
- Testing
- Finerenone (BAY94-8862)
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 206 people
- Sponsor
- Bayer
Diabete Mellitus, Cognitive Impairment
Predicting the Risk of Diabetic Neurodegenerative Disorders by Artificial Intelligence Tools Based on Retinal Imaging
Diabetic Retinopathy (DR) is the most frequent complication of diabetes, and its presence and severity are related to the appearance of both micro and macrovascular events.
- Trial name
- NCT06541834
- Testing
- Retinal imaging
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Ospedale San Raffaele
Diabetic Retinopathy, Melatonin
Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm
This study evaluates the effect of melatonin 4 mg on circadian rhythm and visual function of patients with diabetes mellitus. Half of the patients will receive melatonin (arm-1) and the other half will receive placebo (arm-2)…
- Conditions
- Diabetic Retinopathy, Melatonin, Circadian Dysrhythmia, Circadian Rhythm Sleep Disorder, Unspecified Type
- Trial name
- NCT03478306
- Testing
- Melatonin 4 mg Tablet
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Diabetic Macular Edema
Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of…
- Trial name
- NCT01319487
- Testing
- 2304 Eye Drops High Dose, 2304 Eye Drops Low Dose
- Where
- 65 sites in United States, Australia and 8 more
- Volunteers
- 267 people
- Sponsor
- Fovea Pharmaceuticals SA
Diabetic Macular Edema
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
The purpose of this study is to evaluate the pharmacokinetics, safety and preliminary efficacy of 3 doses of Cand5. Cand5 is a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
- Trial name
- NCT00306904
- Testing
- bevasiranib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- OPKO Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.